Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Omiganan topical gel: Phase II data

In a Phase II trial in 240 patients with moderate to severe rosacea, both 1% and 2.5%

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE